Related Experiment Video

Updated: Aug 20, 2026

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Ursodeoxycholic acid inhibits endothelin-1 production in human vascular endothelial cells

Ji Ma1, Haruko Iida, Taisuke Jo

  • 1Department of Cardiovascular Medicine, Respiratory Medicine, and Gastroenterology, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8645, Japan.

European Journal of Pharmacology
|November 24, 2004
PubMed

Insights

Ursodeoxycholic acid effectively reduces endothelin-1 production in human endothelial cells, independent of nitric oxide. This suggests potential therapeutic benefits for liver diseases like cirrhosis and portal hypertension by improving endothelial function.

Area of Science:

  • Hepatology
  • Endothelial Biology
  • Pharmacology

Background:

  • Endothelin-1 (ET-1) plays a key role in hepatobiliary diseases, particularly cirrhosis and portal hypertension.
  • Understanding factors influencing ET-1 production is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the impact of ursodeoxycholic acid (UDCA) and its conjugates on ET-1 and nitric oxide (NO) production in human endothelial cells.
  • To elucidate the role of NO in mediating UDCA's effects on ET-1 production.

Main Methods:

  • Human umbilical vein endothelial cells (HUVECs) were treated with UDCA and its conjugates.
  • ET-1 and NO levels were quantified using ELISA and Griess assay.
  • mRNA expression of ET-1 and endothelial nitric oxide synthase (eNOS) was analyzed via RT-PCR.

Main Results:

  • UDCA inhibited ET-1 production in a dose-dependent manner.
  • Higher concentrations of UDCA increased NO production.
  • UDCA decreased ET-1 mRNA expression, with no significant change in eNOS mRNA.
  • NO inhibition did not affect UDCA's inhibitory action on ET-1.

Conclusions:

  • UDCA directly inhibits ET-1 production in human endothelial cells.
  • The inhibitory effect of UDCA on ET-1 is independent of nitric oxide.
  • UDCA may improve endothelial function, offering a potential therapeutic strategy for cirrhosis-related complications like portal hypertension.

More Related Videos

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research08:42

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research

Published on: October 22, 2014

In vivo Liver Endocytosis Followed by Purification of Liver Cells by Liver Perfusion12:35

In vivo Liver Endocytosis Followed by Purification of Liver Cells by Liver Perfusion

Published on: November 10, 2011

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...